Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
KPV
Also known as: Lys-Pro-Val, Alpha-MSH Fragment 11-13
KPV is a C-terminal tripeptide fragment of alpha-melanocyte stimulating hormone (alpha-MSH). Unlike full-length alpha-MSH, KPV retains anti-inflammatory activity without melanocortin receptor binding or skin-darkening effects. Preclinical research suggests potent anti-inflammatory action, particularly in gut inflammation models, but human clinical data is essentially absent.
Risk Level
Low RiskDifficulty
Beginner| Molecular Formula | C16H30N4O5 |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Enters cells and directly inhibits NF-kB signaling by preventing nuclear translocation of the p65 subunit. Reduces pro-inflammatory cytokine production (TNF-alpha, IL-6, IL-1beta) independent of melanocortin receptors. Shows activity in colitis models via direct interaction with intestinal epithelial cells.
Dosing Research
No established human dosing. Underground protocols include subcutaneous injection (200-500 mcg/day), oral capsules (200-500 mcg/day for gut-targeted use), and topical application for skin conditions. Cycle length varies widely.
Side Effects & Risks
Very limited safety data in humans. Considered theoretically low-risk given its derivation from an endogenous peptide. No significant adverse effects reported in preclinical studies. Oral bioavailability and systemic effects from oral dosing are poorly characterized.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.